PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE

PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE

Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 x 109/l at baseline coul...

Full description

Bibliographic Details
Main Authors: Simone Baldini, Luigi Rigacci, Valentina Carrai, Renato Alterini, Rajmonda Fjerza, Alberto Bosi
Format: Article
Language:English
Published: PAGEPress Publications 2012-06-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
ITP
romiplostim: platelet count
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/371

Internet

http://www.mjhid.org/index.php/mjhid/article/view/371

Similar Items